Effron, Mark B.
Nair, Kavita V.
Molife, Cliff
Keller, Stuart Y.
Page, Robert L. II
Simeone, Jason C.
Murphy, Brian
Nordstrom, Beth L.
Zhu, Yajun
McCollam, Patrick L.
Vetrovec, George W.
Funding for this research was provided by:
Daiichi-Sankyo
Eli Lilly and Company
Article History
First Online: 8 December 2017
Compliance with ethical standards
:
: This study was funded by Daiichi Sankyo Inc., Parsippany, NJ, USA, and Eli Lilly and Company, Indianapolis, IN, USA.
: MBE is a shareholder of, receives a pension from, and—at the time of the study—was an employee of Eli Lilly and Company. CM, SK, YZ, and PLM are shareholders and employees of Eli Lilly and Company. GV is an unpaid consultant to Daiichi Sankyo and Eli Lilly. KVN and RLP II are paid consultants to Daiichi Sankyo and Eli Lilly. JCS, BLN, and BM are employed by Evidera, which received funding from Eli Lilly and Company and Daiichi Sankyo Inc. to conduct this research.